Sight Sciences to be Acquired by NovaSight Affiliate

TL;DR

Sight Sciences is getting bought out by NovaSight's affiliate, deal expected to close Q4 2024.

AI Summary

Sight Sciences, Inc. announced on September 26, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of NovaSight Ltd. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition will combine two companies focused on innovative ophthalmic technologies.

Why It Matters

This acquisition signifies a consolidation in the ophthalmic technology sector, potentially impacting the competitive landscape and future product development for eye care solutions.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant being acquired
• NovaSight Ltd. (company) — Acquiring entity's affiliate
• September 26, 2024 (date) — Date of the announcement and definitive agreement
• fourth quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT Nasdaq Glo

Filing Documents

• sght-20240926.htm (8-K) — 52KB
• 0000950170-24-109665.txt ( ) — 179KB
• sght-20240926.xsd (EX-101.SCH) — 32KB
• sght-20240926_htm.xml (XML) — 5KB

01. Other Events

Item 8.01. Other Events On September 26, 2024, Noridian Healthcare Solutions, the Medicare Administrative Contractor ("MAC") for sixteen (16) states and U.S. territories, published a final local coverage determination and related final local coverage article (collectively, the "Final LCD") regarding Micro-Invasive Glaucoma Surgery ("MIGS"). The Final LCD, which is substantially similar to the proposed LCD published by Noridian in May 2024, confirms Medicare coverage for phacoemulsification / intraocular lens placement procedures performed with a single MIGS procedure. A "MIGS" procedure includes canaloplasty in combination with trabeculotomy ab interno, which is a procedural description associated with the Company's OMNI Surgical System ("OMNI"), and goniotomy, which is a procedural description associated with the Company's SION Surgical Instrument ("SION") technology. Accordingly, Medicare coverage for canaloplasty in combination with trabeculotomy ab interno and goniotomy procedures will continue in the states covered by this MAC. The LCD has an effective date of November 17, 2024. The Final LCD adopts coverage limitations or non-coverage policies for MIGS procedures as first-line treatments for mild-to-moderate glaucoma, for surgical MIGS procedures (such as canaloplasty or goniotomy) when performed at the same time of service in the same patient eye as an aqueous shunt procedure, and for when phacoemulsification / intraocular lens placement is performed with a combination of MIGS procedures (e.g., cataract + stent + canaloplasty or goniotomy) at the same time of service in the same eye. The Company plans to continue to engage with each MAC, the Centers for Medicare and Medicaid Services, and the clinical societies in continued support of procedures performed with OMNI and SION. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this "Current Report"), together with other statements and information publicly disseminate

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: September 26, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR